SK BIOPHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80,700 KRW | +1.00% |
|
+2.28% | -19.62% |
| May. 10 | SK Biopharmaceuticals Turns to Profit in Q1 as Sales Jump 88% | MT |
| Jan. 30 | SK Biopharmaceuticals Swings to Profit in Q4 | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,234,939 | 7,612,048 | 5,646,385 | 7,862,650 | 6,319,879 | - | - |
| Enterprise Value (EV) 2 | 12,865 | 7,293 | 5,353 | 7,766 | 6,199 | 6,102 | 6,007 |
| P/E ratio | -49 x | 117 x | -40.5 x | -239 x | 162 x | 50.1 x | 27.9 x |
| Yield | - | - | - | - | - | - | 0.06% |
| Capitalization / Revenue | 515 x | 18.2 x | 22.9 x | 22.2 x | 12.8 x | 9.81 x | 7.8 x |
| EV / Revenue | 501 x | 17.4 x | 21.7 x | 21.9 x | 12.6 x | 9.47 x | 7.41 x |
| EV / EBITDA | -55.6 x | 68.4 x | -45.3 x | -350 x | 98.1 x | 33.6 x | 20.2 x |
| EV / FCF | -58 x | -75 x | -32.5 x | -80.4 x | 263 x | 54.2 x | 37.5 x |
| FCF Yield | -1.72% | -1.33% | -3.08% | -1.24% | 0.38% | 1.84% | 2.67% |
| Price to Book | 34.9 x | 17.1 x | 17.8 x | 27.7 x | 19.8 x | 14.6 x | 10 x |
| Nbr of stocks (in thousands) | 78,313 | 78,313 | 78,313 | 78,313 | 78,313 | - | - |
| Reference price 3 | 169,000 | 97,200 | 72,100 | 100,400 | 80,700 | 80,700 | 80,700 |
| Announcement Date | 2/8/21 | 2/8/22 | 2/9/23 | 1/29/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 123.9 | 25.69 | 418.6 | 246.2 | 354.9 | 492.7 | 644.3 | 810.2 |
| EBITDA 1 | - | -231.2 | 106.6 | -118.1 | -22.2 | 63.22 | 181.7 | 296.8 |
| EBIT 1 | - | -239.5 | 94.96 | -131.1 | -37.09 | 48.11 | 162.7 | 290 |
| Operating Margin | - | -932.32% | 22.68% | -53.24% | -10.45% | 9.76% | 25.25% | 35.79% |
| Earnings before Tax (EBT) 1 | - | -240.2 | 71.28 | -142.5 | -42.58 | 40.44 | 149.4 | 247.9 |
| Net income 1 | - | -247.7 | 64.85 | -139.4 | -33.93 | 37.63 | 118.1 | 210.3 |
| Net margin | - | -964.34% | 15.49% | -56.64% | -9.56% | 7.64% | 18.32% | 25.96% |
| EPS 2 | -1,100 | -3,448 | 828.0 | -1,780 | -420.0 | 497.2 | 1,609 | 2,894 |
| Free Cash Flow 3 | - | -221,749 | -97,188 | -164,831 | -96,586 | 23,589 | 112,550 | 160,317 |
| FCF margin | - | -863,221.34% | -23,214.67% | -66,955.81% | -27,215.73% | 4,787.37% | 17,467.82% | 19,788.28% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 37,314.77% | 61,947.64% | 54,012.33% |
| FCF Conversion (Net income) | - | - | - | - | - | 62,683.56% | 95,325.57% | 76,229.76% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 50.00 |
| Announcement Date | 4/14/20 | 2/8/21 | 2/8/22 | 2/9/23 | 1/29/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 164 | 230.7 | 41.14 | 53.43 | 88.83 | 62.77 | 60.78 | 77.01 | 90.34 | 126.8 | 114 | 115.4 | 125.3 | 136.5 | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | 14.66 | 14.4 | 19.7 | 21.5 | - | - |
| EBIT 1 | 10.85 | 134.4 | -37.14 | -40.07 | -9.247 | -44.62 | -22.66 | -18.94 | -10.71 | 15.21 | 10.3 | 7.917 | 14.12 | 19.7 | - | - |
| Operating Margin | 6.62% | 58.23% | -90.26% | -74.99% | -10.41% | -71.09% | -37.27% | -24.59% | -11.86% | 12% | 9.03% | 6.86% | 11.26% | 14.43% | - | - |
| Earnings before Tax (EBT) 1 | - | 52.68 | -35.01 | - | -16.62 | -46.55 | -2.494 | -25.05 | -19.82 | 4.796 | 7.758 | 1.3 | 10.57 | 15.17 | - | - |
| Net income 1 | 61.99 | 47.13 | -35.21 | - | -14.96 | -43.86 | -2.369 | -23.34 | -13.93 | 5.708 | 12.83 | 5.5 | 14.9 | 27.1 | - | - |
| Net margin | 37.81% | 20.42% | -85.56% | - | -16.84% | -69.88% | -3.9% | -30.31% | -15.42% | 4.5% | 11.26% | 4.76% | 11.89% | 19.85% | - | - |
| EPS 2 | - | - | -450.0 | -580.0 | -191.0 | -560.0 | -30.00 | -298.0 | -235.0 | 86.00 | 164.0 | 107.2 | 257.2 | -16.63 | 160.3 | 231.2 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/10/21 | 2/8/22 | 5/16/22 | 8/11/22 | 11/10/22 | 2/9/23 | 5/10/23 | 8/10/23 | 11/9/23 | 1/29/24 | 5/9/24 | - | - | - | - | - |
1KRW in Billions2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 370 | 319 | 293 | 96.6 | 121 | 218 | 313 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 2 | - | -221,749 | -97,188 | -164,831 | -96,586 | 23,589 | 112,550 | 160,317 |
| ROE (net income / shareholders' equity) | - | -135% | 19.8% | -36.7% | -11% | 12.3% | 31.7% | 39.4% |
| ROA (Net income/ Total Assets) | - | -77.1% | 11.3% | -21.3% | -4.74% | 3.99% | 14.6% | 21.7% |
| Assets 1 | - | 321.3 | 571.9 | 653.9 | 715.9 | 942.4 | 806.1 | 968.1 |
| Book Value Per Share 3 | - | 4,840 | 5,672 | 4,042 | 3,622 | 4,078 | 5,542 | 8,050 |
| Cash Flow per Share 3 | - | -2,936 | - | -2,042 | -1,203 | 657.0 | 1,693 | 2,667 |
| Capex 1 | - | 11 | 4.32 | 4.91 | 2.39 | 7.91 | 8.62 | 8.36 |
| Capex / Sales | - | 42.91% | 1.03% | 1.99% | 0.67% | 1.61% | 1.34% | 1.03% |
| Announcement Date | 4/14/20 | 2/8/21 | 2/8/22 | 2/9/23 | 1/29/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
80,700
KRW
Average target price
107,438
KRW
Spread / Average Target
+33.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.62% | 4.53B | |
| +3.89% | 71.18B | |
| +30.13% | 9.61B | |
| +28.63% | 4.73B | |
| +18.41% | 3.68B | |
| -36.16% | 2.03B | |
| +19.51% | 1.96B | |
| -39.38% | 1.81B | |
| -45.43% | 1.71B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- A326030 Stock
- Financials SK Biopharmaceuticals Co., Ltd.
